News

GE sequences stem cells in China
Enlarge image

ResearchUK

GE sequences stem cells in China

13.06.2012 - A new partnership will bring GE Healthcare information on racial genetic variations in stem cells.

Chalfont St Giles/Bejing  – GE Healthcare has launched a stem cell cooperation in China. Together with the Bejing Genomics Institute (BGI), the UK-based healthcare unit of the US technology major will perform a multi-year research collaboration in stem cell science. The Chinese sequencing specialist will help to explore the underlying genetic variation between ethnically diverse human stem cell lines, which may help to help advance the potential of stem cell-derived assays for use in drug discovery and toxicity testing. 

GE and the BGI made the collaboration public at a special signing ceremony attended by Amr Abid, General Manager Cell Technologies at GE Healthcare Life Sciences and the three leading executives from the BGI. Two projects are planned in the frame of the cooperation. As a first project, BGI is performing genome sequencing and epigenetic analysis on cardiomyocytes and hepatocytes supplied by GE Healthcare Life Sciences. The aim is to map the genetic variation across an ethnically diverse range of stem cell lines and to examine the changes that occur during differentiation into specific cell types. As a basis for the second project, GE Healthcare will provide BGI with a IN Cell Analyzer 2000 system for high content cellular imaging analysis. The analyzer will be used by BGI to investigate gene function for a library of previously sequenced cell types by over-expressing or blocking the activity of single genes and observing the effect in selected populations of cells.

http://www.european-biotechnology-news.com/news/news/2012-02/ge-sequences-stem-cells-in-china.html

RegulationItalyGermanyNetherlandsEU

28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

Events

All Events

Current issue

All issues

Product of the week

Products